The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform
Harutsugu Tatebe - One of the best experts on this subject based on the ideXlab platform.
-
monoclonal Antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the alzheimer s disease diagnosis
Scientific Reports, 2016Co-Authors: Kazuma Murakami, Maki Tokuda, Takashi Suzuki, Yumi Irie, Mizuho Hanaki, Naotaka Izuo, Yoko Monobe, Kenichi Akagi, Ryotaro Ishii, Harutsugu TatebeAbstract:Amyloid β-protein (Aβ42) oligomerization is an early event in Alzheimer's disease (AD). Current diagnostic methods using sequence-specific antibodies against less toxic fibrillar and monomeric Aβ42 run the risk of overdiagnosis. Hence, conformation-specific antibodies against neurotoxic Aβ42 oligomers have garnered much attention for developing more accurate Diagnostics. Antibody 24B3, highly specific for the toxic Aβ42 conformer that has a turn at Glu22 and Asp23, recognizes a putative Aβ42 dimer, which forms stable and neurotoxic oligomers more potently than the monomer. 24B3 significantly rescues Aβ42-induced neurotoxicity, whereas sequence-specific antibodies such as 4G8 and 82E1, which recognizes the N-terminus, do not. The ratio of toxic to total Aβ42 in the cerebrospinal fluid of AD patients is significantly higher than in control subjects as measured by sandwich ELISA using antibodies 24B3 and 82E1. Thus, 24B3 may be useful for AD diagnosis and therapy.
Kazuma Murakami - One of the best experts on this subject based on the ideXlab platform.
-
monoclonal Antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the alzheimer s disease diagnosis
Scientific Reports, 2016Co-Authors: Kazuma Murakami, Maki Tokuda, Takashi Suzuki, Yumi Irie, Mizuho Hanaki, Naotaka Izuo, Yoko Monobe, Kenichi Akagi, Ryotaro Ishii, Harutsugu TatebeAbstract:Amyloid β-protein (Aβ42) oligomerization is an early event in Alzheimer's disease (AD). Current diagnostic methods using sequence-specific antibodies against less toxic fibrillar and monomeric Aβ42 run the risk of overdiagnosis. Hence, conformation-specific antibodies against neurotoxic Aβ42 oligomers have garnered much attention for developing more accurate Diagnostics. Antibody 24B3, highly specific for the toxic Aβ42 conformer that has a turn at Glu22 and Asp23, recognizes a putative Aβ42 dimer, which forms stable and neurotoxic oligomers more potently than the monomer. 24B3 significantly rescues Aβ42-induced neurotoxicity, whereas sequence-specific antibodies such as 4G8 and 82E1, which recognizes the N-terminus, do not. The ratio of toxic to total Aβ42 in the cerebrospinal fluid of AD patients is significantly higher than in control subjects as measured by sandwich ELISA using antibodies 24B3 and 82E1. Thus, 24B3 may be useful for AD diagnosis and therapy.
Ekaterina N Lebedenko - One of the best experts on this subject based on the ideXlab platform.
-
fluorescent immunolabeling of cancer cells by quantum dots and Antibody scfv fragment
Journal of Biomedical Optics, 2009Co-Authors: Tatiana A Zdobnova, S G Dorofeev, Piter N Tananaev, R B Vasiliev, T Balandin, E F Edelweiss, Oleg A Stremovskiy, Irina V Balalaeva, I V Turchin, Ekaterina N LebedenkoAbstract:Semiconductor quantum dots QDs coupled with cancer-specific targeting ligands are new promising agents for fluorescent visualization of cancer cells. Human epidermal growth factor receptor 2/neu HER2/neu, over- expressed on the surface of many cancer cells, is an im- portant target for cancer Diagnostics. Antibody scFv frag- ments as a targeting agent for direct delivery of fluorophores offer significant advantages over full-size an- tibodies due to their small size, lower cross-reactivity, and immunogenicity. We have used quantum dots linked to anti-HER2/neu 4D5 scFv Antibody to label HER2/neu- overexpressing live cells. Labeling of target cells was shown to have high brightness, photostability, and speci- ficity. The results indicate that construction based on quantum dots and scFv Antibody can be successfully used for cancer cell visualization. © 2009 Society of Photo-Optical Instru-
Maki Tokuda - One of the best experts on this subject based on the ideXlab platform.
-
monoclonal Antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the alzheimer s disease diagnosis
Scientific Reports, 2016Co-Authors: Kazuma Murakami, Maki Tokuda, Takashi Suzuki, Yumi Irie, Mizuho Hanaki, Naotaka Izuo, Yoko Monobe, Kenichi Akagi, Ryotaro Ishii, Harutsugu TatebeAbstract:Amyloid β-protein (Aβ42) oligomerization is an early event in Alzheimer's disease (AD). Current diagnostic methods using sequence-specific antibodies against less toxic fibrillar and monomeric Aβ42 run the risk of overdiagnosis. Hence, conformation-specific antibodies against neurotoxic Aβ42 oligomers have garnered much attention for developing more accurate Diagnostics. Antibody 24B3, highly specific for the toxic Aβ42 conformer that has a turn at Glu22 and Asp23, recognizes a putative Aβ42 dimer, which forms stable and neurotoxic oligomers more potently than the monomer. 24B3 significantly rescues Aβ42-induced neurotoxicity, whereas sequence-specific antibodies such as 4G8 and 82E1, which recognizes the N-terminus, do not. The ratio of toxic to total Aβ42 in the cerebrospinal fluid of AD patients is significantly higher than in control subjects as measured by sandwich ELISA using antibodies 24B3 and 82E1. Thus, 24B3 may be useful for AD diagnosis and therapy.
Takashi Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
monoclonal Antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the alzheimer s disease diagnosis
Scientific Reports, 2016Co-Authors: Kazuma Murakami, Maki Tokuda, Takashi Suzuki, Yumi Irie, Mizuho Hanaki, Naotaka Izuo, Yoko Monobe, Kenichi Akagi, Ryotaro Ishii, Harutsugu TatebeAbstract:Amyloid β-protein (Aβ42) oligomerization is an early event in Alzheimer's disease (AD). Current diagnostic methods using sequence-specific antibodies against less toxic fibrillar and monomeric Aβ42 run the risk of overdiagnosis. Hence, conformation-specific antibodies against neurotoxic Aβ42 oligomers have garnered much attention for developing more accurate Diagnostics. Antibody 24B3, highly specific for the toxic Aβ42 conformer that has a turn at Glu22 and Asp23, recognizes a putative Aβ42 dimer, which forms stable and neurotoxic oligomers more potently than the monomer. 24B3 significantly rescues Aβ42-induced neurotoxicity, whereas sequence-specific antibodies such as 4G8 and 82E1, which recognizes the N-terminus, do not. The ratio of toxic to total Aβ42 in the cerebrospinal fluid of AD patients is significantly higher than in control subjects as measured by sandwich ELISA using antibodies 24B3 and 82E1. Thus, 24B3 may be useful for AD diagnosis and therapy.